MAP2K7 and neoplasm: Indeed, recent studies in TBNC featuring activation of RAS signaling pathways demonstrated that co-targeting of MEK and PD-L1 results in upregulation of MHC I and II on tumor cells and increase in CD8 T cell infiltration [146].